Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594082 | 1.00 | SLC5A2 (0.45) | SLC5A2ADAPYGLHIF1A | |
| SCHEMBL30025957 | 1.00 | SLC5A2 (0.45) | SLC5A2ADAPYGLHIF1A | |
| SCHEMBL7048838 | 0.73 | P2RY2 (0.60) | SLC5A2PYGL | |
| SCHEMBL6395173 | 0.73 | P2RY2 (0.60) | SLC5A2PYGL | |
| SCHEMBL937118 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL509237 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL5163143 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL6884830 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL6935273 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A | |
| SCHEMBL8791673 | 0.72 | KDM4E (0.54) | ADAPYGLHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-1603476-A2 | METHOD OF TATTOO REMOVAL | 3M Innovative Properties Company (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1601365-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M Innovative Properties Company (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080292-A2 | METHOD OF TATTOO REMOVAL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004078138-A2 | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | SLC5A2 2629/4885ADA 471/4885PYGL 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.